BMY (bristol myers squibb) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BMY (bristol myers squibb)

BMY 42.64

-0.4%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DewDiligence_on_SI who wrote (133)	2/5/2018 2:13:54 PM
From: Miljenko Zuanic	Read Replies (1) of 194

One do not need to be "Salamon" to figure out that hTMB will hurt response to chemo (resistance level increase), while may be simple neutral to IO. Neoantigen hypothesis need to be proven first, which right now it is not. That is why I said "BS". At this point, I do not share your confidence that BMY will hold Nivo growth rate! All indications where N-W chombo are used will be too expensive (with treatment cost rise due to SAE) to justify benefit, IMO. I may be wrong, but it is my gut-filing.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next